TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04832607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multivirus (CMV, EBV, AdV)-specific T cells
Description: Cell therapy product which is individually produced for each patient and administered via IV bolus injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multivirus (CMV, EBV, AdV)-specific T cells
Description: Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
Study: NCT03537976

Intervention type: OTHER
Group type: OTHER
Intervention: Static Images and Facial Videos
Description: 2D and 3D still and video images obtained from each patient before surgery.
Study: NCT02026791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: * The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme-LMA
Description: * The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted.
Study: NCT02445040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Babylog VN500 in HFOV Mode
Description: Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
Study: NCT01873170

Intervention type: DRUG
Intervention: levonorgestrel exposure

Intervention type: DRUG
Intervention: levonorgestrel exposure

Intervention type: DRUG
Intervention: DMPA exposure

Intervention type: DRUG
Intervention: etonogestrel exposure

Intervention type: DEVICE
Intervention: IUD insertion

Intervention type: DEVICE
Intervention: IUD insertion

Intervention type: DEVICE
Intervention: subdermal contraceptive implant insertion
Study: NCT03021356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic xenograft
Description: After randomization, the aortic xenograft is implanted in the standard fashion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic xenograft
Description: After randomization, the aortic xenograft is implanted in the standard fashion
Study: NCT00648128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: single-dose 500 mg immediate-release oral dose'
Study: NCT02486289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NBMI Placebo
Study: NCT03220399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-1 (P)
Description: 1capsule, single oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-2 (T)
Description: 1tablet, single oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-1 and NVP-1603-2 (P+T)
Description: 1capsule and 1tablet co-administration, oral single dosing
Study: NCT01301391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib Maleate
Description: 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity.
Study: NCT02133599

Intervention type: DRUG
Group type: OTHER
Intervention: IOHEXOL
Description: Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
Study: NCT02423681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoSmart
Description: Heated humidification as first intention (HH1st) with ThermoSmart
Study: NCT02005029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02801500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Anastomosis
Description: A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
Study: NCT00761410

Intervention type: DEVICE
Group type: OTHER
Intervention: P.F.C. Sigma RP-F Total Knee Replacement
Description: An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
Study: NCT03781362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-100
Description: CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-100
Description: CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
Study: NCT03033602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written exposure therapy
Description: five sessions of writing about traumatic experience.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT, cognitive only
Description: 12 sessions of cognitive therapy related to traumatic experience.
Study: NCT03048292

Intervention type: OTHER
Intervention: Acute Endovascular Stroke Treatment

Intervention type: OTHER
Intervention: Acute Endovascular Stroke Treatment

Intervention type: OTHER
Intervention: Acute Endovascular Stroke Treatment
Study: NCT02720198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomilnacipran
Description: treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
Study: NCT02423681

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Without ThermoSmart
Description: ThermoSmart is switched off
Study: NCT04237805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF-189s
Description: 20mg，40mg，80mg，120mg，160mg，210mg，once daily
Study: NCT01222195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day by mouth on days 1-21 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: 200 mcg subcutaneously every 2 weeks of a 28 cycle.
Study: NCT02745821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Wire Certus, St. Jude Medical, USA
Description: FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
Study: NCT01966003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered 200 mg/m² IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered 200 mg/m² IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 215
Description: Administered 15 mg/kg Q3W by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered 15 mg/kg Q3W by IV infusion
Study: NCT03909984

Intervention type: DEVICE
Group type: OTHER
Intervention: Nightwatch
Description: Nocturnal monitoring for 2 months with three different seizure detection devices.
Study: NCT04068350

Intervention type: OTHER
Intervention: Pain questionnaire
Description: Pain questionnaire, 3 months after surgery
Study: NCT03645967

Intervention type: DEVICE
Group type: OTHER
Intervention: ReadyCleanse Cloths
Description: ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
Study: NCT05976204

Intervention type: PROCEDURE
Intervention: ToF primary repair
Description: ToF primary repair for patients with ToF
Study: NCT02235246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
Study: NCT04492358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone 60 mg/day, in a single dose, during 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: The standard treatment used in each site will be administered to the patients assigned to the control group.
Study: NCT03773458

Intervention type: DEVICE
Group type: OTHER
Intervention: An artificial system for the screening of scoliosis
Description: An artificial intelligence to make evaluation of scoliosis using back images
Study: NCT02082925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient has to get up his hand when he defined his dyspnea threshold during 6MWT
Study: NCT02994914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco Geriatric Evaluation
Description: Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco Geriatric Evaluation
Description: Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco Geriatric Evaluation
Description: Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy.
Study: NCT03447080

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: White Bread containing 50g carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: White Bread containing 50g carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ricebran soybean milk
Description: White Bread with rice bran soybean milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean milk
Description: White Bread with soybean milk
Study: NCT01431001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Description: The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Description: The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
Study: NCT02150018

Intervention type: OTHER
Intervention: non invasive ventilation
Study: NCT03062722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: keyhole approach
Description: The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
Study: NCT01477853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet orally daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin tablet orally daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to atorvastatin
Description: Placebo to atorvastatin tablet orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (open-label)
Description: Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (open-label)
Description: Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (open-label)
Description: Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (open-label)
Description: Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (open-label)
Description: Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride (double-blind)
Description: Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glimepiride
Description: Phase B: placebo to glimepiride tablet orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glimepiride
Description: Phase B: placebo to glimepiride tablet orally daily.
Study: NCT02098980

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study: NCT00187226

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
Study: NCT02009670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C inulin
Description: Oral 13C inulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral maltodextrin
Study: NCT01235546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and standard of care
Description: 500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and standard of care
Description: 250 cc normal saline, plus standard of care (cephazolin or clindamycin)
Study: NCT02846090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine to reduce the IOP
Description: Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine to reduce the IOP
Description: Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine to reduce the IOP
Description: Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
Study: NCT01742377

Intervention type: PROCEDURE
Intervention: Patients with GerdQ positive
Description: Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.

Intervention type: PROCEDURE
Intervention: Patients with GerdQ negative
Description: Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.

Intervention type: PROCEDURE
Intervention: Normal volunteers
Description: Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
Study: NCT00003796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study: NCT04354987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391 10/10mg
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391 10/10mg
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391 10/10mg
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391 10/10mg
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D090, D337
Description: D090 and D337 co-administration(Other Name: Reference drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D090, D337
Description: D090 and D337 co-administration(Other Name: Reference drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D090, D337
Description: D090 and D337 co-administration(Other Name: Reference drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D090, D337
Description: D090 and D337 co-administration(Other Name: Reference drug)
Study: NCT02557841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
Study: NCT00580814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: methylphenidate treatment
Description: subjects received mehtylphenidate treatment for 12 months